Cargando…

The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease

Despite the reality that a death from cerebrovascular accident occurs every 3.5 min in the United States, there are few therapeutic options which are typically limited to a narrow window of opportunity in time for damage mitigation and recovery. Novel therapies have targeted pathological processes s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Jonah, Lockard, Gavin, Monsour, Molly, Alayli, Adam, Borlongan, Cesario V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332234/
https://www.ncbi.nlm.nih.gov/pubmed/35892653
http://dx.doi.org/10.3390/antiox11081447
_version_ 1784758596146298880
author Gordon, Jonah
Lockard, Gavin
Monsour, Molly
Alayli, Adam
Borlongan, Cesario V.
author_facet Gordon, Jonah
Lockard, Gavin
Monsour, Molly
Alayli, Adam
Borlongan, Cesario V.
author_sort Gordon, Jonah
collection PubMed
description Despite the reality that a death from cerebrovascular accident occurs every 3.5 min in the United States, there are few therapeutic options which are typically limited to a narrow window of opportunity in time for damage mitigation and recovery. Novel therapies have targeted pathological processes secondary to the initial insult, such as oxidative damage and peripheral inflammation. One of the greatest challenges to therapy is the frequently permanent damage within the CNS, attributed to a lack of sufficient neurogenesis. Thus, recent use of cell-based therapies for stroke have shown promising results. Unfortunately, stroke-induced inflammatory and oxidative damage limit the therapeutic potential of these stem cells. Nuclear factor erythroid 2-related factor 2 (Nrf2) has been implicated in endogenous antioxidant and anti-inflammatory activity, thus presenting an attractive target for novel therapeutics to enhance stem cell therapy and promote neurogenesis. This review assesses the current literature on the concomitant use of stem cell therapy and Nrf2 targeting via pharmaceutical and natural agents, highlighting the need to elucidate both upstream and downstream pathways in optimizing Nrf2 treatments in the setting of cerebrovascular disease.
format Online
Article
Text
id pubmed-9332234
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93322342022-07-29 The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease Gordon, Jonah Lockard, Gavin Monsour, Molly Alayli, Adam Borlongan, Cesario V. Antioxidants (Basel) Review Despite the reality that a death from cerebrovascular accident occurs every 3.5 min in the United States, there are few therapeutic options which are typically limited to a narrow window of opportunity in time for damage mitigation and recovery. Novel therapies have targeted pathological processes secondary to the initial insult, such as oxidative damage and peripheral inflammation. One of the greatest challenges to therapy is the frequently permanent damage within the CNS, attributed to a lack of sufficient neurogenesis. Thus, recent use of cell-based therapies for stroke have shown promising results. Unfortunately, stroke-induced inflammatory and oxidative damage limit the therapeutic potential of these stem cells. Nuclear factor erythroid 2-related factor 2 (Nrf2) has been implicated in endogenous antioxidant and anti-inflammatory activity, thus presenting an attractive target for novel therapeutics to enhance stem cell therapy and promote neurogenesis. This review assesses the current literature on the concomitant use of stem cell therapy and Nrf2 targeting via pharmaceutical and natural agents, highlighting the need to elucidate both upstream and downstream pathways in optimizing Nrf2 treatments in the setting of cerebrovascular disease. MDPI 2022-07-26 /pmc/articles/PMC9332234/ /pubmed/35892653 http://dx.doi.org/10.3390/antiox11081447 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gordon, Jonah
Lockard, Gavin
Monsour, Molly
Alayli, Adam
Borlongan, Cesario V.
The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease
title The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease
title_full The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease
title_fullStr The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease
title_full_unstemmed The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease
title_short The Role of Concomitant Nrf2 Targeting and Stem Cell Therapy in Cerebrovascular Disease
title_sort role of concomitant nrf2 targeting and stem cell therapy in cerebrovascular disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332234/
https://www.ncbi.nlm.nih.gov/pubmed/35892653
http://dx.doi.org/10.3390/antiox11081447
work_keys_str_mv AT gordonjonah theroleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT lockardgavin theroleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT monsourmolly theroleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT alayliadam theroleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT borlongancesariov theroleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT gordonjonah roleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT lockardgavin roleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT monsourmolly roleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT alayliadam roleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease
AT borlongancesariov roleofconcomitantnrf2targetingandstemcelltherapyincerebrovasculardisease